Hospitals are always looking for ways to reduce readmission rates. They may have an unusual ally in a quality control system originally developed in Europe for the manufacturing sector. Read more about it.
John R. Washlick, Buchanan, Ingersoll & Rooney, and expert in healthcare system transactions and market consolidation, talks to Managed Healthcare Executive about healthcare spin-offs, what that means for the future of mergers and acquisitions, and advice for healthcare executives.
Understanding the key barriers to biosimilar adoption in the U.S. is the first step managed care executives can take to overcome these obstacles, according to a Trinity Parners report.
How are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.